Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...